Go to deals
Healthcare

Doetsch Grether has received valuation services

Located in the heart of Basel, Switzerland, Doetsch Grether AG is a medium-sized, family-owned company with traditional values that specializes in the marketing and distribution of products in the pharma, OTC and consumer care segments.

Doetsch Grether’s portfolio consists of its own brands, such as the famous Grether’s Pastilles®, neo-angin® and Sulgan®N, as well as distribution brands that include Magnesium-Diasporal®, Tiger Balm® and Pearl Drops®, which are successfully sold throughout Switzerland.

Oaklins’ team in Switzerland has repeatedly advised Doetsch Grether on valuation topics, contract drafting and the preparation of second opinions in connection with various acquisition projects.

“We consider Oaklins to be a very reliable and flexible partner who has always supported us competently and in a goal-oriented manner, even in hectic situations. Oaklins has been an important sparring partner for us in various projects.”

Lukas Grimm

CFO, Doetsch Grether AG

Talk to the deal team

Jens Rutten

Partner
Zurich, Switzerland
Oaklins Switzerland

Related deals

Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Healthcare

Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.

Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.

Learn more
Afric Phar has been acquired by Pharma Capital
Healthcare

Afric Phar has been acquired by Pharma Capital

Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.

Learn more
Xiel Limited has been acquired by MIS Healthcare
Private Equity | Healthcare

Xiel Limited has been acquired by MIS Healthcare

MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.

Learn more